IBRX: Company disclosure

Item 7.01 Regulation FD Disclosure. On October 14, 2026, ImmunityBio, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) to include patients with BCG-unresponsive NMIBC with papillary-only tumors. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 99.1* Press Release dated October 14, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Furnished herewith. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: October 14, 2026 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer